{"entity":{"id":"aramis","kind":"trial","name":"ARAMIS","aka":[],"tldr":"ARAMIS showed that darolutamide, an androgen receptor blocker that barely enters the brain, delayed metastases and lengthened life in men whose prostate cancer was rising on hormone therapy but not yet visible on scans, with side effects close to placebo.","summary":"ARAMIS randomised 1509 men with non-metastatic castration-resistant prostate cancer and a PSA doubling time of ten months or less two to one to darolutamide or placebo alongside androgen deprivation. The primary endpoint was metastasis-free survival.\n\nDarolutamide lengthened metastasis-free survival substantially and improved overall survival in the final analysis, with rates of fatigue, falls, fractures, seizures and cognitive effects that were close to placebo, a tolerability profile attributed to its low penetration of the blood-brain barrier. It was approved in the United States in July 2019 and is often preferred among the three androgen receptor inhibitors for this setting in older men.","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT02200614","url":"https://clinicaltrials.gov/study/NCT02200614"}],"tags":["subtype-trials"],"related":[],"cancers":["prostate-nmcrpc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["darolutamide"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["karim-fizazi"],"bottlenecks":[],"keyPapers":["paper-aramis-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02200614","phase":"3","setting":"High-risk non-metastatic castration-resistant prostate cancer: darolutamide against placebo, both with continued androgen deprivation","sponsor":"Bayer","result":"Darolutamide lengthened metastasis-free and overall survival compared with placebo with a near-placebo side-effect profile; approved in July 2019.","yearReported":2019,"enrolled":1509,"outcomes":[]},"route":"/trials/aramis/","neighbours":{"cancer":[{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}],"person":[{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/"}],"paper":[{"id":"paper-aramis-nejm-2019","kind":"paper","name":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-aramis-nejm-2019/"}]}}